New pill KDS2010 aims to shed pounds in obesity trial

NCT ID NCT07009171

Recruiting now Disease control Sponsor: NeuroBiogen Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called KDS2010 for weight loss in 75 overweight or obese adults. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see how much weight they lose and if the drug is safe. It is a Phase 2a trial, meaning it is still early and mainly checks if the drug works and what dose might be best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KDS2010
What this could lead to: If successful, KDS2010 could offer a new oral medication for weight loss in people who are overweight or obese.
What could go wrong: This is an early Phase 2a trial with only 75 participants, so results may not confirm effectiveness or safety. Weight loss drugs often have side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE PATIENTS OBESITY OVERWEIGHT

Contacts and locations

Locations

Kangbuk Samsung Medical Center
RECRUITING

Seoul, Seoul, 03181, South Korea
The Catholic University of Korea, St. Vincent's Hospital
RECRUITING

Suwon, Gyeonggi-do, 16247, South Korea
Yonsei University Health System, Severance Hospital
RECRUITING

Seoul, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.